Prospective Long-Term Follow-up after First-Line Subcutaneous Cladribine Treatment in Patients with Hairy Cell Leukemia. a Study of the SAKK (Swiss Group for Clinical Cancer Research)
Rudolf Benz(Kantonsspital Münsterlingen), Georg Stüssi(Institute of Oncology Research), Felicitas Hitz(Kantonsspital St. Gallen), Kornelius Arn(Luzerner Kantonsspital), Reinhard Zenhäusern, Thomas Pabst(University Hospital of Bern), Sabine Blum(University of Lausanne), Ulrich Mey(Kantonsspital Graubünden), Alix O’Meara(University Hospital of Basel), Simona Berardi(Swiss Group For Clinical Cancer Research), Urban Novak(University of Bern), Mario Bargetzi(Kantonsspital Aarau), Nathan Cantoni(Kantonsspital Aarau), Martin Andres(University of Bern), Andreas Lohri(Kantonsspital St. Gallen), Yves Chalandon(University of Geneva), Willy Nettekoven(Hospital Neuchâtel), Qiyu Li(Army Medical University), Daniel Rauch(Washington University in St. Louis)
Cited by 0
Related Papers
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|568
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
|Journal of Clinical Oncology|2009|562
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
|The Lancet|2015|392
Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia
|Blood|2015|377
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2016|347